Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
A. Vassiliou (Athens, Greece), A. Zacharis (Athens, Greece), C. Keskinidou (Athens, Greece), E. Jahaj (Athens, Greece), P. Gallos (Athens, Greece), N. Athanasiou (Athens, Greece), S. Tsipilis (Athens, Greece), I. Dimopoulou (Athens, Greece), A. Kotanidou (Athens, Greece), S. Orfanos (Athens, Greece). Biomarkers for activation of the inflammatory and immune systems in the risk of mortality in critically-ill COVID-19 patients. 3321

Member's Comments

No comment yet.

Related content which might interest you: Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Role of biomarkers of systemic inflammation in the prediction of mortality and/or severe complications in community adquired pneumonia Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk? Source: Eur Respir J, 58 (1) 2100342; 10.1183/13993003.00342-2021 Year: 2021 Inflammatory biomarkers as predictors of intubation and mortality in severe COVID-19 Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Investigation the role of pentraxin-3 in the innate immune system in patients with COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Effect of autoimmune diseases on risk and survival in histology-specific lung cancer Source: Eur Respir J 2012; 40: 1489-1495 Year: 2012 Risk factors contributing to mortality in patients with COPD developing acute respiratory failure Source: Eur Respir J 2007; 30: Suppl. 51, 557s Year: 2007 Immunotherapy improves inflammatory cytokines, humoral immunity and cellular immunity in septic patients Source: Annual Congress 2010 - Pulmonary infections and sepsis Year: 2010 Immune system dysregulation in chronic lung disease Source: Eur Respir J 2011; 38: 500-501 Year: 2011 Inflammatory bowel disease and risk of mortality in COPD Source: Eur Respir J 2016; 47:1357-1364 Year: 2016 CD4 as a predictor of systemic inflammatory response and death at severe community-acquired pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit Source: Eur Respir Rev, 27 (150) 180061; 10.1183/16000617.0061-2018 Year: 2018 Early-life pulmonary immunity and development of paediatric inflammatory respiratory diseases Source: International Congress 2019 – Early origins of lung disease: an interdisciplinary approach Year: 2019 Interleukin-10 polymorphisms influence the neonatal immune response and may be a risk factor for childhood allergic disease and wheeze Source: Annual Congress 2011 - Inflammation and genes in childhood asthma Year: 2011 Analysis of causes of death and mortality risk factors in elderly patients hospitalized due to pneumonia Source: International Congress 2018 – Difficult-to-treat respiratory infections Year: 2018 Long-term risks of cardiovascular events in patients with chronic kidney disease who survived sepsis Source: International Congress 2016 – Sepsis and ARDS: looking forward Year: 2016 Risk factors for mortality in patients with COPD exacerbation Source: Annual Congress 2009 - Epidemiology of COPD Year: 2009 Assessment of humoral immune response and the incidence of acquired infections in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 174s Year: 2003